- Investing Ideas
- /
- South Korean Pharmaceuticals & Biotech Undervalued based on future growth
South Korean Pharmaceuticals & Biotech Undervalued based on future growth
Results
5
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
5 companies
Hugel
Market Cap: ₩2.3t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩214,000.00
7D
-18.3%
1Y
-27.7%
DongKook Pharmaceutical
Market Cap: ₩778.9b
Produces and sells pharmaceutical products in South Korea and internationally.
A086450
₩17,410.00
7D
-1.5%
1Y
-1.9%
Dong-A Socio Holdings
Market Cap: ₩680.3b
Engages in the pharmaceutical business in South Korea.
A000640
₩105,700.00
7D
-2.6%
1Y
-11.3%
Chong Kun Dang Holdings
Market Cap: ₩214.5b
Manufactures and distributes pharmaceutical products in South Korea and internationally.
A001630
₩45,050.00
7D
-0.3%
1Y
-20.7%
Daihan PharmaceuticalLtd
Market Cap: ₩174.9b
Engages in the manufacture and sale of therapeutic drugs in South Korea.
A023910
₩29,750.00
7D
2.4%
1Y
17.1%